Abiopharma

🔍 Adams Brian (Executive)

Company: Kymera Therapeutics, Inc. (KYMR)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Acquired 52,500 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: A | equity_swap_involved: false | shares_owned_after: 52,500.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 105,000 shares of Stock Option (Right to Buy) at $43.3 per share (Derivative)
  Date: 2025-09-03 | Code: A | Expires: 2035-09-02 | equity_swap_involved: false | shares_owned_after: 105,000.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following September 3, 2025, subject to the reporting person's continued employment through each vesting date.
• F2: Twenty-five percent (25%) of the shares underlying this stock option shall vest on September 3, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.